Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-48,030
Closed -$1.33M – 1849
2026
Q2
$1.33M Sell
48,030
-1,769
-4% -$39.1K 0.01% 816
2026
Q1
$728K Buy
49,799
+393
+0.8% +$5.77K 0.01% 1022
2025
Q4
$624K Buy
49,406
+724
+1% +$10.7K 0.01% 986
2025
Q3
$749K Buy
48,682
+5,825
+14% +$93.9K 0.01% 1027
2025
Q2
$674K Buy
42,857
+5,417
+14% +$82.1K 0.01% 1030
2025
Q1
$715K Buy
37,440
+7,343
+24% +$161K 0.01% 941
2024
Q4
$718K Buy
30,097
+1,852
+7% +$51.7K 0.01% 930
2024
Q3
$791K Buy
28,245
+1,520
+6% +$42.9K 0.01% 866
2024
Q2
$699K Buy
26,725
+5,518
+26% +$115K 0.01% 895
2024
Q1
$464K Buy
21,207
+2,138
+11% +$45.8K 0.01% 1019
2023
Q4
$444K Sell
19,069
-17,249
-47% -$347K 0.01% 999
2023
Q3
$717K Buy
36,318
+2,548
+8% +$50.2K 0.01% 806
2023
Q2
$766K Sell
33,770
-45,863
-58% -$924K 0.02% 811
2023
Q1
$1.56M Sell
79,633
-8,386
-10% -$161K 0.03% 528
2022
Q4
$1.51M Buy
+88,019
New +$1.56M 0.03% 519

Other funds holding RXO

Oppenheimer & Co's RXO Position: Q3 2026 in Review

Oppenheimer & Co sold out of RXO (RXO) in Q3 2026, closing a stake of 48,030 shares — an estimated $1.33M sold.

Oppenheimer & Co first reported a position in RXO in Q4 2022 and held it in 15 quarters. The position peaked at $1.56M in Q1 2023. 307 funds tracked by Wall St. Rank hold RXO as of Q3 2026.

  • Oppenheimer & Co reported no remaining RXO position as of Q3 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 48,030 RXO shares in Q3 2026, an estimated $1.33M.
  • Oppenheimer & Co first reported a position in RXO in Q4 2022 and held it in 15 quarters.
  • Oppenheimer & Co's RXO position peaked at $1.56M in Q1 2023.
  • 307 funds tracked by Wall St. Rank held RXO as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.